New drugs for human African trypanosomiasis:a twenty first century success story

Dickie, E. A., Giordani, F. , Gould, M. K., Maeser, P., Burri, C., Mottram, J. C. , Rao, S. P.S. and Barrett, M. P. (2020) New drugs for human African trypanosomiasis:a twenty first century success story. Tropical Medicine and Infectious Disease, 5(1), 29. (doi: 10.3390/tropicalmed5010029) (PMID:32092897) (PMCID:PMC7157223)

[img] Text
207973.pdf - Published Version
Available under License Creative Commons Attribution.



The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associated with other medical crises ravaging the continent. A series of dedicated interventions and the introduction of innovative routes to develop drugs, involving Product Development Partnerships, has led to a dramatic turnaround in the fight against HAT caused by Trypanosoma brucei gambiense. The World Health Organization have been able to optimize the use of existing tools to monitor and intervene in the disease. A promising new oral medication for stage 1 HAT, pafuramidine maleate, ultimately failed due to unforeseen toxicity issues. However, the clinical trials for this compound demonstrated the possibility of conducting such trials in the resource-poor settings of rural Africa. The Drugs for Neglected Disease initiative (DNDi), founded in 2003, has developed the first all oral therapy for both stage 1 and stage 2 HAT in fexinidazole. DNDi has also brought forward another oral therapy, acoziborole, potentially capable of curing both stage 1 and stage 2 disease in a single dosing. In this review article, we describe the remarkable successes in combating HAT through the twenty first century, bringing the prospect of the elimination of this disease into sight.

Item Type:Articles
Additional Information:This research was funded by The Wellcome Trust WT-103024MA.
Glasgow Author(s) Enlighten ID:Dickie, Dr Emily and Gould, Matthew and Giordani, Dr Federica and Barrett, Professor Michael and Mottram, Professor Jeremy
Creator Roles:
Dickie, E.Writing – review and editing
Giordani, F.Writing – review and editing
Gould, M.Writing – review and editing
Mottram, J.Writing – review and editing
Barrett, M.Writing – review and editing
Authors: Dickie, E. A., Giordani, F., Gould, M. K., Maeser, P., Burri, C., Mottram, J. C., Rao, S. P.S., and Barrett, M. P.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Tropical Medicine and Infectious Disease
ISSN (Online):2414-6366
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in Tropical Medicine and Infectious Disease 5(1):29
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
170547The Wellcome Centre for Molecular Parasitology ( Core Support )Andrew WatersWellcome Trust (WELLCOTR)104111/Z/14/ZRIII - Parasitology